查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1822371

2032 年Fluoroquinolones市场预测：按类型、频谱、给药途径、代数、适应症和地区进行的全球分析

Fluoroquinolones Market Forecasts to 2032 - Global Analysis By Type (Oral Fluoroquinolones, Injectable Fluoroquinolones, and Other Types), Spectrum, Route of Administration, Generation, Indication and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3个工作天内

价格

根据 Stratistics MRC 的数据，全球Fluoroquinolones市场预计在 2025 年达到 49.5 亿美元，到 2032 年将达到 80.5 亿美元，预测期内的复合年增长率为 7.2%。

Fluoroquinolones药物是一类合成抗生素，以其广谱抗细菌感染活性而闻名。其主要作用是抑制DNA旋转酶和拓朴异构酶IV，这两种酵素是细菌DNA加工所必需的。它们常用于治疗肺部、泌尿道、消化器官系统和皮肤感染疾病。虽然Fluoroquinolones口服有效且方便，但由于存在相关风险，包括断裂、神经系统併发症以及细菌抗药性的产生，因此必须谨慎使用。

根据世界卫生组织（WHO）2023年的报告，东南亚是全球结核病新发病例最多的地区，占全球结核病新病例的45.0%，约占全球结核病新病例的87.0%。

细菌感染增加

随着诊断能力的提升和对抗菌素抗药性认识的不断加深，医疗保健提供者正优先考虑使用频谱药物进行快速介入。Fluoroquinolones因其对革兰氏阴性和革兰氏阳性病原体的有效性，在住院和门诊环境中的使用日益增多。分子诊断技术的进步使得病原体识别更加快速，从而支持有针对性的抗生素使用。人口老化和免疫力缺乏患者数量的增加进一步推高了感染率和抗生素消费量。日益加重的临床负担正在推动对下一代Fluoroquinolones及其给药系统的持续投资。

严重的副作用和安全问题

美国食品药物管理局 (FDA) 和欧洲药品管理局 (EMA) 等监管机构发布了黑框警告和使用限制，影响了医生的处方行为。药物安全检测平台和人工智慧驱动的不利事件追踪技术正在帮助更密切地监测药物的安全性。关于长期毒性和微生物组破坏的新研究呼吁更谨慎地使用药物。这些担忧正在减缓市场扩张，尤其是在药品核准框架严格的地区。因此，製造商正在投资研发配方改良的药物和风险缓解策略，以恢復临床可信度。

门诊抗生素治疗需求不断增加

门诊治疗的转变加速了对便利、广效口服Fluoroquinolones的需求。远端医疗平台和远距离诊断正在加快处方流程，特别是对于併发症感染疾病。缓释性和患者友善给药方案的创新正在提高依从性和治疗效果。医疗保健系统越来越倾向于具有成本效益的门诊治疗，以减轻医院负担并改善资源分配。在新兴市场，基层医疗和数位医疗工具的普及正在扩大抗生素的覆盖范围，使其扩展到都市区以外。这一趋势为客製化包装、网路药局分销和行动医疗整合创造了新的机会。

学名药竞争加剧

专利到期正推动低成本替代品的激增，尤其是在Ciprofloxacin和levofloxacin等高用量领域。监管机构对学名药核准的支持和简化的生物等效性试验正在加速市场准入。数位采购平台和医院集中竞标鼓励学名药而非品牌药的大量采购。为了保持竞争力，原厂药厂正专注于差异化配方、联合治疗和生命週期管理策略。然而，由于缺乏明显的临床优势，品牌Fluoroquinolones在成熟市场和新兴市场都面临失败的风险。

COVID-19的影响

新冠疫情扰乱了抗生素供应链，改变了处方模式，尤其是在尖峰时段。Fluoroquinolones并非第一线抗病毒药物，而是用于治疗新冠患者的继发性细菌感染疾病。封锁和生产延误导致了抗生素暂时短缺，迫使各国政府重新评估抗生素库存和分配通讯协定。监管机构推出了紧急使用途径，并加快了基本抗生素的核准。疫情后的策略如今强调供应链的韧性、抗菌药物管理以及人工智慧在感染疾病监测中的整合。

口服Fluoroquinolones预计将在预测期内占据最大的市场份额

由于口服Fluoroquinolones药物广泛用于治疗社区性感染症，预计该类药物将在预测期内占据最大的市场份额。口服Fluoroquinolones生物利用度高、给药方便、疗效范围广，是门诊治疗的理想选择。片剂包覆和控制释放机制的创新提高了患者的依从性，并最大限度地减少了胃肠道副作用。医院和诊所越来越多地采用口服疗法，以减少住院时间和医疗成本。网路药局平台和行动医疗应用程式的兴起进一步促进了口服抗生素的可及性。在对分散治疗的需求不断增长的背景下，口服Fluoroquinolones在销售量和价值方面继续保持领先地位。

预计呼吸道感染疾病领域在预测期内将达到最高复合年增长率

预计呼吸道感染疾病领域将在预测期内达到最高成长率。Fluoroquinolones因其强大的抗呼吸道病原体活性，常用于治疗支气管炎、肺炎和鼻窦炎。就地检验和人工智慧辅助放射学的进步使得诊断速度更快、治疗更有针对性。季节性流行病和空气污染相关併发症导致都市区抗生素处方量增加。医疗保健提供者正在采用Fluoroquinolones药物治疗第一线治疗无效的抗药性菌株。该领域也受益于正在探索新的组合和可吸入製剂以增强肺部输送的临床试验。

占比最高的地区：

由于感染率高且医疗基础设施不断扩张，预计亚太地区将在预测期内占据最大的市场份额。由于人口稠密和卫生条件有限，中国、印度和印尼等国家的抗生素消费量正在上升。政府正在采取措施推动本地製造和学名药生产，以满足日益增长的需求。该地区还正在采用数位健康平台和行动诊断技术，以改善农村地区Fluoroquinolones的可及性。全球製药公司与本地经销商之间的策略合作伙伴关係正在推动供应链效率的提升。

复合年增长率最高的地区：

在先进的医疗体系和强劲的研发投入的支持下，北美地区预计将在预测期内呈现最高的复合年增长率。美国和加拿大在抗生素管理、精准诊断和人工智慧处方分析方面发挥主导作用。监管机构正在简化新型Fluoroquinolones衍生物和联合治疗的核准途径。医院正在整合电子健康记录和预测演算法，以优化抗生素使用并降低抗药性。该地区也受益于强大的报销框架和广泛采用的门诊护理模式。随着药物传递和製剂创新的加速，北美将继续塑造Fluoroquinolones的未来。

免费客製化服务

此报告的订阅者可以选择以下免费自订选项之一：

  • 公司简介
    • 对最多三家其他市场公司进行全面分析
    • 主要企业的SWOT分析（最多3家公司）
  • 区域细分
    • 根据客户兴趣对主要国家进行的市场估计、预测和复合年增长率（註：基于可行性检查）
  • 竞争基准化分析
    • 根据产品系列、地理分布和策略联盟对主要企业基准化分析

目录

第一章执行摘要

第二章 前言

  • 概述
  • 相关利益者
  • 调查范围
  • 调查方法
    • 资料探勘
    • 数据分析
    • 数据检验
    • 研究途径
  • 研究材料
    • 主要研究资料
    • 次级研究资讯来源
    • 先决条件

第三章市场走势分析

  • 驱动程式
  • 抑制因素
  • 机会
  • 威胁
  • 新兴市场
  • COVID-19的影响

第四章 波特五力分析

  • 供应商的议价能力
  • 买方的议价能力
  • 替代品的威胁
  • 新进入者的威胁
  • 竞争对手之间的竞争

5. 全球Fluoroquinolones市场类型

  • 口服Fluoroquinolones
  • 注射用Fluoroquinolones药物
  • 其他类型

6. 全球Fluoroquinolones药物市场（频谱）

  • 窄频频谱
  • 频谱

7. 全球Fluoroquinolones市场（依给药途径）

  • 口服
  • 眼药水
  • 静脉
  • 滴鼻剂

8. 全球Fluoroquinolones市场（依代数）

  • 第一代
  • 第二代
  • 第三代
  • 第四代

9. 全球Fluoroquinolones市场（按适应症）

  • 呼吸道感染疾病
  • 眼部感染疾病
  • 尿道感染
  • 胃肠道感染疾病
  • 性行为感染传染病
  • 皮肤和软组织感染疾病
  • 其他适应症

10. 全球Fluoroquinolones药物市场（按地区）

  • 北美洲
    • 美国
    • 加拿大
    • 墨西哥
  • 欧洲
    • 德国
    • 英国
    • 义大利
    • 法国
    • 西班牙
    • 其他欧洲国家
  • 亚太地区
    • 日本
    • 中国
    • 印度
    • 澳洲
    • 纽西兰
    • 韩国
    • 其他亚太地区
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地区
  • 中东和非洲
    • 沙乌地阿拉伯
    • 阿拉伯聯合大公国
    • 卡达
    • 南非
    • 其他中东和非洲地区

第十一章 重大进展

  • 协议、伙伴关係、合作和合资企业
  • 收购与合併
  • 新产品发布
  • 业务扩展
  • 其他关键策略

第 12 章：公司概况

  • Bayer AG
  • Aurobindo Pharma
  • Pfizer Inc.
  • Dr. Reddy's Laboratories
  • Novartis AG
  • Glenmark Pharmaceuticals
  • Sanofi
  • Mylan NV
  • GlaxoSmithKline plc
  • Cipla Ltd.
  • Johnson & Johnson
  • Lupin Pharmaceuticals
  • Merck & Co., Inc.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC31125

According to Stratistics MRC, the Global Fluoroquinolones Market is accounted for $4.95 billion in 2025 and is expected to reach $8.05 billion by 2032 growing at a CAGR of 7.2% during the forecast period. Fluoroquinolones represent a group of synthetic antibiotics known for their broad activity against bacterial infections. Their primary action involves blocking DNA gyrase and topoisomerase IV, enzymes necessary for bacterial DNA processes. They are often prescribed for infections of the lungs, urinary tract, digestive system, and skin. While effective and convenient for oral administration, fluoroquinolones must be used carefully because of associated risks such as tendon rupture, nerve complications, and antibiotic resistance development.

According to the World Health Organization report in 2023, the highest number of new tuberculosis (TB) cases were reported in the Southeast Asia region, accounting for 45.0% of total cases, and amongst these, approximately 87.0% of new TB cases.

Market Dynamics:

Driver:

Rising prevalence of bacterial infections

As diagnostic capabilities improve and awareness of antimicrobial resistance grows, healthcare providers are prioritizing broad-spectrum agents for rapid intervention. Fluoroquinolones are increasingly used in both inpatient and outpatient settings due to their efficacy against gram-negative and gram-positive pathogens. Technological advancements in molecular diagnostics are enabling faster pathogen identification, supporting targeted antibiotic use. The aging population and rise in immunocompromised patients are further contributing to infection rates and antibiotic consumption. This growing clinical burden is driving sustained investment in next-generation fluoroquinolone formulations and delivery systems.

Restraint:

Severe side effects and safety concerns

Regulatory agencies like the FDA and EMA have issued black-box warnings and usage restrictions, impacting physician prescribing behavior. The integration of pharmacovigilance platforms and AI-driven adverse event tracking is helping monitor safety profiles more rigorously. Emerging research on long-term toxicity and microbiome disruption is prompting calls for more selective use. These concerns are slowing market expansion, especially in regions with stringent drug approval frameworks. As a result, manufacturers are investing in reformulated compounds and risk-mitigation strategies to restore clinical confidence.

Opportunity:

Rising demand for outpatient antibiotic treatments

The shift toward outpatient care is accelerating demand for oral fluoroquinolones that offer convenience and broad-spectrum coverage. Telemedicine platforms and remote diagnostics are enabling faster prescription workflows, especially for uncomplicated infections. Innovations in extended-release formulations and patient-friendly dosing regimens are improving adherence and therapeutic outcomes. Healthcare systems are increasingly favouring cost-effective outpatient treatments to reduce hospital burden and improve resource allocation. In emerging markets, rising access to primary care and digital health tools is expanding antibiotic reach beyond urban centres. This trend is opening new opportunities for tailored packaging, e-pharmacy distribution, and mobile health integration.

Threat:

Increasing generic competition

Patent expirations have led to a proliferation of low-cost alternatives, particularly in high-volume segments like ciprofloxacin and levofloxacin. Regulatory support for generic approvals and streamlined bioequivalence testing is accelerating market entry. Digital procurement platforms and centralized hospital tenders are favouring bulk purchases of generics over branded options. To remain competitive, originator companies are focusing on differentiated formulations, combination therapies, and lifecycle management strategies. However, without clear clinical superiority, branded fluoroquinolones risk losing ground in both mature and emerging markets.

Covid-19 Impact

The COVID-19 pandemic disrupted antibiotic supply chains and altered prescribing patterns, especially during peak hospitalization periods. While fluoroquinolones were not frontline antivirals, they were used to manage secondary bacterial infections in COVID patients. Lockdowns and manufacturing delays led to temporary shortages, prompting governments to reassess antibiotic stockpiling and distribution protocols. Regulatory bodies introduced emergency use pathways and fast-track approvals for essential antimicrobials. Post-pandemic strategies now emphasize supply chain resilience, antimicrobial stewardship, and integration of AI in infection surveillance.

The oral fluoroquinolones segment is expected to be the largest during the forecast period

The oral fluoroquinolones segment is expected to account for the largest market share during the forecast period, due to its widespread use in treating community-acquired infections. These formulations offer high bioavailability, ease of administration, and broad-spectrum efficacy, making them ideal for outpatient care. Technological innovations in tablet coatings and controlled-release mechanisms are enhancing patient compliance and minimizing gastrointestinal side effects. Hospitals and clinics are increasingly adopting oral regimens to reduce inpatient stays and healthcare costs. The rise of e-pharmacy platforms and mobile health apps is further boosting access to oral antibiotics. As demand for decentralized treatment grows, oral fluoroquinolones continue to lead in both volume and revenue.

The respiratory tract infections segment is expected to have the highest CAGR during the forecast period

Over the forecast period, the respiratory tract infections segment is predicted to witness the highest growth rate, fuelled by rising incidence and diagnostic improvements. Fluoroquinolones are often prescribed for bronchitis, pneumonia, and sinusitis due to their potent action against respiratory pathogens. Advances in point-of-care testing and AI-assisted radiology are enabling quicker diagnosis and targeted therapy. Seasonal outbreaks and air pollution-related complications are increasing antibiotic prescriptions in urban centers. Healthcare providers are adopting fluoroquinolones for resistant strains where first-line treatments fail. This segment is also benefiting from clinical trials exploring novel combinations and inhalable formulations for enhanced pulmonary delivery.

Region with largest share:

During the forecast period, the Asia Pacific region is expected to hold the largest market share driven by high infection rates and expanding healthcare infrastructure. Countries like China, India, and Indonesia are witnessing increased antibiotic consumption due to population density and limited sanitation. Government initiatives are promoting local manufacturing and generic production to meet rising demand. The region is also embracing digital health platforms and mobile diagnostics to improve rural access to fluoroquinolones. Strategic collaborations between global pharma firms and regional distributors are enhancing supply chain efficiency.

Region with highest CAGR:

Over the forecast period, the North America region is anticipated to exhibit the highest CAGR, supported by advanced healthcare systems and robust R&D investment. The U.S. and Canada are leading in antimicrobial stewardship, precision diagnostics, and AI-driven prescription analytics. Regulatory agencies are streamlining approval pathways for novel fluoroquinolone derivatives and combination therapies. Hospitals are integrating electronic health records and predictive algorithms to optimize antibiotic use and reduce resistance. The region also benefits from strong reimbursement frameworks and widespread adoption of outpatient care models. As innovation in drug delivery and formulation accelerates, North America continues to shape the future of fluoroquinolone therapeutics.

Key players in the market

Some of the key players profiled in the Fluoroquinolones Market include Bayer AG, Aurobindo Pharma, Pfizer Inc., Dr. Reddy's Laboratories, Novartis AG, Glenmark Pharmaceuticals, Sanofi, Mylan N.V., GlaxoSmithKline plc, Cipla Ltd., Johnson & Johnson, Lupin Pharmaceuticals, Merck & Co., Inc., Sun Pharmaceutical Industries Ltd., and Teva Pharmaceutical Industries Ltd.

Key Developments:

In September 2025, Bayer announced the launch of Bayer Co.Lab AdVenture, a new platform for its Bayer Co.Lab global life sciences incubator network, which aims to connect venture capital partners globally. Bayer Co.Lab AdVenture bridges tenants of high-potential biotech startups with leading venture capital firms, accelerating access to global financing and investment networks, thereby advancing the translation of early-stage ideas into impactful global solutions.

In September 2025, Pfizer Inc. and BioNTech SE announced positive topline results from an ongoing Phase 3 clinical trial cohort evaluating the safety, tolerability, and immunogenicity of a 30-µg dose of the LP.8.1-adapted monovalent COMIRNATY(R) (COVID-19 Vaccine, mRNA) 2025-2026 Formula in adults aged 65 and older and in adults aged 18 through 64 with at least one underlying risk condition for severe COVID-19.

Types Covered:

  • Oral Fluoroquinolones
  • Injectable Fluoroquinolones
  • Other Types

Spectrums Covered:

  • Narrow-Spectrum
  • Broad-Spectrum

Route of Administrations Covered:

  • Oral
  • Ophthalmic
  • Intravenous
  • Otic

Generations Covered:

  • First Generation
  • Second Generation
  • Third Generation
  • Fourth Generation

Indications Covered:

  • Respiratory Tract Infections
  • Ophthalmic Infections
  • Urinary Tract Infections
  • Gastrointestinal Infections
  • Sexually Transmitted Diseases
  • Skin and Soft Tissue Infections
  • Other Indications

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2024, 2025, 2026, 2028, and 2032
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 Emerging Markets
  • 3.7 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Fluoroquinolones Market, By Type

  • 5.1 Introduction
  • 5.2 Oral Fluoroquinolones
  • 5.3 Injectable Fluoroquinolones
  • 5.4 Other Types

6 Global Fluoroquinolones Market, By Spectrum

  • 6.1 Introduction
  • 6.2 Narrow-Spectrum
  • 6.3 Broad-Spectrum

7 Global Fluoroquinolones Market, By Route of Administration

  • 7.1 Introduction
  • 7.2 Oral
  • 7.3 Ophthalmic
  • 7.4 Intravenous
  • 7.5 Otic

8 Global Fluoroquinolones Market, By Generation

  • 8.1 Introduction
  • 8.2 First Generation
  • 8.3 Second Generation
  • 8.4 Third Generation
  • 8.5 Fourth Generation

9 Global Fluoroquinolones Market, By Indication

  • 9.1 Introduction
  • 9.2 Respiratory Tract Infections
  • 9.3 Ophthalmic Infections
  • 9.4 Urinary Tract Infections
  • 9.5 Gastrointestinal Infections
  • 9.6 Sexually Transmitted Diseases
  • 9.7 Skin and Soft Tissue Infections
  • 9.8 Other Indications

10 Global Fluoroquinolones Market, By Geography

  • 10.1 Introduction
  • 10.2 North America
    • 10.2.1 US
    • 10.2.2 Canada
    • 10.2.3 Mexico
  • 10.3 Europe
    • 10.3.1 Germany
    • 10.3.2 UK
    • 10.3.3 Italy
    • 10.3.4 France
    • 10.3.5 Spain
    • 10.3.6 Rest of Europe
  • 10.4 Asia Pacific
    • 10.4.1 Japan
    • 10.4.2 China
    • 10.4.3 India
    • 10.4.4 Australia
    • 10.4.5 New Zealand
    • 10.4.6 South Korea
    • 10.4.7 Rest of Asia Pacific
  • 10.5 South America
    • 10.5.1 Argentina
    • 10.5.2 Brazil
    • 10.5.3 Chile
    • 10.5.4 Rest of South America
  • 10.6 Middle East & Africa
    • 10.6.1 Saudi Arabia
    • 10.6.2 UAE
    • 10.6.3 Qatar
    • 10.6.4 South Africa
    • 10.6.5 Rest of Middle East & Africa

11 Key Developments

  • 11.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 11.2 Acquisitions & Mergers
  • 11.3 New Product Launch
  • 11.4 Expansions
  • 11.5 Other Key Strategies

12 Company Profiling

  • 12.1 Bayer AG
  • 12.2 Aurobindo Pharma
  • 12.3 Pfizer Inc.
  • 12.4 Dr. Reddy's Laboratories
  • 12.5 Novartis AG
  • 12.6 Glenmark Pharmaceuticals
  • 12.7 Sanofi
  • 12.8 Mylan N.V.
  • 12.9 GlaxoSmithKline plc
  • 12.10 Cipla Ltd.
  • 12.11 Johnson & Johnson
  • 12.12 Lupin Pharmaceuticals
  • 12.13 Merck & Co., Inc.
  • 12.14 Sun Pharmaceutical Industries Ltd.
  • 12.15 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Fluoroquinolones Market Outlook, By Region (2024-2032) ($MN)
  • Table 2 Global Fluoroquinolones Market Outlook, By Type (2024-2032) ($MN)
  • Table 3 Global Fluoroquinolones Market Outlook, By Oral Fluoroquinolones (2024-2032) ($MN)
  • Table 4 Global Fluoroquinolones Market Outlook, By Injectable Fluoroquinolones (2024-2032) ($MN)
  • Table 5 Global Fluoroquinolones Market Outlook, By Other Types (2024-2032) ($MN)
  • Table 6 Global Fluoroquinolones Market Outlook, By Spectrum (2024-2032) ($MN)
  • Table 7 Global Fluoroquinolones Market Outlook, By Narrow-Spectrum (2024-2032) ($MN)
  • Table 8 Global Fluoroquinolones Market Outlook, By Broad-Spectrum (2024-2032) ($MN)
  • Table 9 Global Fluoroquinolones Market Outlook, By Route of Administration (2024-2032) ($MN)
  • Table 10 Global Fluoroquinolones Market Outlook, By Oral (2024-2032) ($MN)
  • Table 11 Global Fluoroquinolones Market Outlook, By Ophthalmic (2024-2032) ($MN)
  • Table 12 Global Fluoroquinolones Market Outlook, By Intravenous (2024-2032) ($MN)
  • Table 13 Global Fluoroquinolones Market Outlook, By Otic (2024-2032) ($MN)
  • Table 14 Global Fluoroquinolones Market Outlook, By Generation (2024-2032) ($MN)
  • Table 15 Global Fluoroquinolones Market Outlook, By First Generation (2024-2032) ($MN)
  • Table 16 Global Fluoroquinolones Market Outlook, By Second Generation (2024-2032) ($MN)
  • Table 17 Global Fluoroquinolones Market Outlook, By Third Generation (2024-2032) ($MN)
  • Table 18 Global Fluoroquinolones Market Outlook, By Fourth Generation (2024-2032) ($MN)
  • Table 19 Global Fluoroquinolones Market Outlook, By Indication (2024-2032) ($MN)
  • Table 20 Global Fluoroquinolones Market Outlook, By Respiratory Tract Infections (2024-2032) ($MN)
  • Table 21 Global Fluoroquinolones Market Outlook, By Ophthalmic Infections (2024-2032) ($MN)
  • Table 22 Global Fluoroquinolones Market Outlook, By Urinary Tract Infections (2024-2032) ($MN)
  • Table 23 Global Fluoroquinolones Market Outlook, By Gastrointestinal Infections (2024-2032) ($MN)
  • Table 24 Global Fluoroquinolones Market Outlook, By Sexually Transmitted Diseases (2024-2032) ($MN)
  • Table 25 Global Fluoroquinolones Market Outlook, By Skin and Soft Tissue Infections (2024-2032) ($MN)
  • Table 26 Global Fluoroquinolones Market Outlook, By Other Indications (2024-2032) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.